Better Health Care ETF: Fidelity's FHLC vs. State Street's XLV

The article compares two healthcare ETFs: XLV and FHLC both charge 0.08% expense ratios, but XLV is more concentrated with 60 holdings versus 365 for FHLC and offers a higher trailing-12-month dividend yield of 1.7% versus 1.4%. FHLC has the higher 1-year return at 18.59% versus 16.86%, while XLV has much larger AUM at $37.5 billion versus $2.9 billion. The piece is largely a fund-comparison and investor-style discussion, with no major catalyst or actionable market event.

Analysis

The real signal here is not “which healthcare ETF is cheaper,” but which risk factor you want embedded in the basket. XLV is effectively a high-conviction, mega-cap biotech/pharma/managed-care proxy with outsized dependence on a handful of balance-sheet compounding stories; that makes it better as a liquidity vehicle and worse as a true sector diversifier. FHLC’s broader footprint should pick up smaller-cap pipeline optionality and M&A convexity, but it also imports more idiosyncratic clinical/regulatory risk, which is why its higher recent return has come with slightly worse drawdown characteristics.

Second-order, the concentration in XLV means any underperformance in LLY or JNJ has an amplified index effect, and the fund can trade more like a “quality growth healthcare” factor than a sector basket. That can be a feature in risk-off tape because these names attract defensive flows, but it also creates hidden fragility if GLP-1 competition, pricing scrutiny, or trial setbacks compress the leadership cohort. FHLC, by contrast, is a cleaner way to express a broad healthcare rebound if the market starts rewarding breadth over mega-cap duration.

The underappreciated catalyst is capital returns and portfolio re-rating: healthcare often becomes attractive when earnings visibility improves and buybacks offset muted top-line growth. If rates continue to drift lower over the next 3-6 months, XLV’s dividend and quality tilt should re-capture inflows faster than FHLC; if volatility rises or antitrust/pricing headlines intensify, FHLC should outperform on relative concentration risk. The consensus is likely underestimating how much of the sector’s index-level behavior is being dictated by just two or three names rather than the broader industry.

The article’s implied “income vs diversification” framing is incomplete: the more actionable distinction is factor exposure — XLV = defensive megacap quality, FHLC = broader healthcare beta with M&A and small-cap upside. In a market where dispersion remains high, the better trade is to own the basket that matches the next catalyst, not the one with the prettier headline yield.

Key Decisions for Investors

• Short-term (1-3 months): Long XLV / short XBI as a defensive-quality vs. unprofitable biotech relative-value trade; XLV should hold up better if rates stay elevated and financing conditions remain tight.
• Medium-term (3-6 months): Buy FHLC on a pullback as a broad-healthcare catch-up trade if healthcare breadth improves; target a 5-8% relative outperformance vs XLV if small/mid-cap healthcare sentiment stabilizes.
• Event-driven: Sell a portion of XLV into strength ahead of binary LLY/JNJ headline risk; XLV’s concentration means a single name surprise can knock 50-100 bps off fund-level returns quickly.
• Options overlay: If you need healthcare exposure but want to cap concentration risk, use a call spread on XLV rather than outright shares; this preserves upside while limiting premium paid for the mega-cap defensiveness premium.
• Pair trade for dispersion: Long FHLC / short XLV if you expect M&A and small-cap rebound over the next 6-12 months; the setup benefits from a broadening tape and is most attractive when mega-cap leadership starts to fade.